WallStSmart

The Ensign Group Inc (ENSG)vsGuardian Pharmacy Services, Inc. (GRDN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 249% more annual revenue ($5.06B vs $1.45B). ENSG leads profitability with a 6.8% profit margin vs 3.4%. ENSG trades at a lower P/E of 35.0x. ENSG earns a higher WallStSmart Score of 57/100 (C).

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34

GRDN

Hold

46

out of 100

Grade: D+

Growth: 6.7Profit: 7.0Value: 5.7Quality: 5.8
Piotroski: 3/9Altman Z: 6.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued
GRDNSignificantly Overvalued (-552.6%)

Margin of Safety

-552.6%

Fair Value

$5.30

Current Price

$37.57

$32.27 premium

UndervaluedFair: $5.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

GRDN3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
6.0610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
26.6%9/10

Every $100 of equity generates 27 in profit

Revenue GrowthGrowth
17.4%8/10

17.4% revenue growth

Areas to Watch

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
3.4%3/10

3.4% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bull Case : GRDN

The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, EPS Growth, Profit Margin. A P/E of 48.2x leaves little room for execution misses. Thin 3.4% margins leave little buffer for downturns.

Key Dynamics to Monitor

ENSG is growing revenue faster at 20.2% — sustainability is the question.

ENSG generates stronger free cash flow (133M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ENSG scores higher overall (57/100 vs 46/100) and 20.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions for the long-term care sector, which includes assisted living and skilled nursing facilities. The company is distinguished by its commitment to personalized medication management, ensuring high standards of quality and compliance while delivering exceptional customer service. Leveraging advanced technology and deep pharmaceutical expertise, Guardian aims to enhance patient outcomes and streamline workflows for its healthcare partners. With a strong operational presence across multiple states, the company is well-positioned to address the growing needs for tailored pharmacy services amidst an evolving healthcare landscape.

Want to dig deeper into these stocks?